US launches Section 301 probe into Germany over drug pricing
- On Thursday, the United States launched a Section 301 investigation into Germany over what it called "persistent underpayment for innovative pharmaceutical products," setting the stage for possible new tariffs.
- President Trump's administration alleges German pricing policies restrict commerce and force Americans to shoulder a "disproportionate share of global pharmaceutical research and development" costs. Germany is fast-tracking legislation to reduce drug spending.
- Stephen Ubl, president of the Pharmaceutical Research and Manufacturers of America, said his organization "appreciates the administration's commitment to challenging unfair practices abroad" and supports using Section 301 to achieve this goal.
- Trade Representative Jamieson Greer suggested the dispute could be resolved through negotiations, pointing to a US-UK deal from earlier this year as a potential model. The White House and German Embassy did not immediately respond.
- Trump has increasingly used trade probes to impose duties after the Supreme Court struck down many sweeping tariffs in February. The administration recently proposed up to 12.5 percent tariffs on dozens of economies under similar investigations.
31 Articles
31 Articles
Germany Faces U.S. Trade Investigation Over Medicine Costs
The Trump administration has launched a trade investigation into Germany’s pharmaceutical pricing policies, arguing that the country pays too little for innovative medicines and shifts a disproportionate share of research costs onto American consumers. 🔎According to U.S. Trade Representative Jamieson Greer, the probe focuses on Germany’s proposed healthcare reforms, which include measures aimed at reducing public spending on prescription drugs.…
The United States on Thursday launched an investigation into Germany's drug pricing policies and other practices, a move that could lead to new tariffs.
US launches tariff probe against Germany under Section 301 over drug pricing | What does it mean for Berlin?
US Trade Representative Jamieson Greer has launched an investigation against Germany under Section 301 of Trade Act over alleged underpayment for innovative pharmaceuticals, a move that could lead to trade measures.
Coverage Details
Bias Distribution
- 58% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
